Estrogenic activity of zearalenone and zearalanol in the neonatal rat uterus.
Fusarium sp. contaminated feedstuffs elicit adverse estrogenic effects in several commercially important animal species via the mycotoxin zearalenone. An estrogenically active synthetic derivative, zearalanol, is used as an anabolic agent in cattle. Since estrogens can irreversibly alter target tissue development, we investigated the estrogenic activity of these compounds in the neonatal rat uterus. Both induced dose-dependent premature uterine growth when injected daily on postnatal days 1-5 (ED50 = 1.3 mg/kg BW). Nuclear estrogen receptor levels dramatically increased 1 hour after either a single injection on day 5 or after five daily injections. In 5-day-old animals, the translocated nuclear receptor was characterized as a single class of binding sites with a dissociation constant (KD) for estradiol (E2) of 1 nM. At 15 days, zearalanol-treated animals showed greater uterine nuclear receptor retention than zearalenone-treated animals. In 5-day-old animals, single mycotoxin doses induced five fold elevations of ornithine decarboxylase (ODC) at 6 hours. Unlike the growth response, ODC dose-response studies showed zearalanol to be about 20-fold more effective than zearalenone. Time course studies revealed that a low dose of zearalenone, but not of zearalanol, resulted in a shift in peak activity from 6 to 8 hours. These data suggest that metabolism of zearalenone may be important in short-term pharmacodynamics. In a competitive binding assay, neither compound competed [3H]E2 from the E2 binding site on alpha-fetoprotein. We conclude that the uterine growth response and ODC induction demonstrate the neonatal estrogenic action of these mycotoxins, apparently mediated via the estrogen receptor. The greater effectiveness of zearalanol in inducing ODC may be related to nuclear retention and/or zearalenone metabolism.
D000818:Animals; D000831:Animals, Newborn; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D009929:Organ Size / Q000187:drug effects; D009955:Ornithine Decarboxylase / Q000096:biosynthesis / Q000378:metabolism; D051381:Rats; D011960:Receptors, Estrogen / Q000187:drug effects / Q000378:metabolism; D012118:Resorcinols / Q000494:pharmacology*; D014599:Uterus / Q000187:drug effects* / Q000201:enzymology / Q000254:growth & development / Q000378:metabolism; D015025:Zearalenone / Q000378:metabolism / Q000494:pharmacology*; D015029:Zeranol / Q000378:metabolism / Q000494:pharmacology*
D011960:Receptors, Estrogen; D012118:Resorcinols; D015025:Zearalenone; D015029:Zeranol; D009955:Ornithine Decarboxylase